Patents by Inventor Hans Peter Wessel

Hans Peter Wessel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8163778
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: April 24, 2012
    Assignee: Hoffmann-LA Roche Inc.
    Inventors: Wolfgang Haap, Paul Hebeisen, Eric Argirios Kitas, Bernd Kuhn, Peter Mohr, Hans Peter Wessel
  • Patent number: 7973051
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: July 5, 2011
    Assignee: Hoffman-La Roche Inc.
    Inventors: Paul Hebeisen, Eric A. Kitas, Rudolf E. Minder, Peter Mohr, Hans Peter Wessel
  • Patent number: 7803819
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: September 28, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Publication number: 20100222340
    Abstract: The present invention relates to compounds of formula (I) wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 2, 2010
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Fabienne Ricklin, Hans Peter Wessel
  • Patent number: 7718666
    Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: May 18, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Bernd Kuhn, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Hans Peter Wessel
  • Publication number: 20090143448
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: November 10, 2008
    Publication date: June 4, 2009
    Inventors: Paul Hebeisen, Eric A. Kitas, Rudolf E. Minder, Peter Mohr, Hans Peter Wessel
  • Publication number: 20090143439
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: November 24, 2008
    Publication date: June 4, 2009
    Inventors: Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Peter Mohr, Hans Peter Wessel
  • Patent number: 7314884
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: January 1, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Publication number: 20070259925
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Application
    Filed: July 17, 2007
    Publication date: November 8, 2007
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Patent number: 7189756
    Abstract: The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: March 13, 2007
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Aebi, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Ulrike Obst, Hans Peter Wessel
  • Patent number: 7071212
    Abstract: The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: wherein R1, E, X1 to X4 and G1 and G2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: July 4, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, Leo Alig, Alexander Chucholowski, Katrin Groebke, Kurt Hilpert, Holger Kuehne, Ulrike Obst, Lutz Weber, Hans Peter Wessel
  • Patent number: 6861440
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: March 1, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Publication number: 20040259902
    Abstract: The present invention relates to compounds of formula (I) 1
    Type: Application
    Filed: June 17, 2004
    Publication date: December 23, 2004
    Inventors: Markus Boehringer, Bernd Kuhn, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Hans Peter Wessel
  • Publication number: 20040242672
    Abstract: The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.
    Type: Application
    Filed: June 30, 2004
    Publication date: December 2, 2004
    Inventors: Johannes Aebi, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Ulrike Obst, Hans Peter Wessel
  • Patent number: 6790860
    Abstract: The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: September 14, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Ulrike Obst, Hans Peter Wessel
  • Publication number: 20040034231
    Abstract: The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: 1
    Type: Application
    Filed: August 12, 2003
    Publication date: February 19, 2004
    Inventors: Jean Ackermann, Leo Alig, Alexander Chucholowski, Katrin Groebke, Kurt Hilpert, Holger Kuehne, Ulrike Obst, Lutz Weber, Hans Peter Wessel
  • Patent number: 6683215
    Abstract: The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: wherein R1, E, X1 to X4 and G1 and G2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: January 27, 2004
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jean Ackermann, Leo Alig, Alexander Chucholowski, Katrin Groebke, Kurt Hilpert, Holger Kuehne, Ulrike Obst, Lutz Weber, Hans Peter Wessel
  • Publication number: 20030199569
    Abstract: The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.
    Type: Application
    Filed: February 25, 2003
    Publication date: October 23, 2003
    Inventors: Johannes Aebi, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Ulrike Obst, Hans Peter Wessel
  • Publication number: 20030083504
    Abstract: The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: 1
    Type: Application
    Filed: October 4, 2002
    Publication date: May 1, 2003
    Inventors: Jean Ackermann, Leo Alig, Alexander Chucholowski, Katrin Groebke, Kurt Hilpert, Holger Kuehne, Ulrike Obst, Lutz Weber, Hans Peter Wessel
  • Patent number: 6548694
    Abstract: N-(4-carbamimidoyl-phenyl)-glycine derivatives have the formula: wherein X and R1 to R5 are as defined herein, and includes hydrates or solvates and/or physiologically acceptable salts thereof and/or physiologically acceptable esters thereof.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: April 15, 2003
    Assignee: Hoffman-La Roche Inc.
    Inventors: Leo Alig, Katrin Groebke Zbinden, Kurt Hilpert, Holger Kuehne, Ulrike Obst, Hans Peter Wessel